Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.

Hiroji Uemura,Kazuki Kobayashi,Akira Yokomizo,Shiro Hinotsu,Shigeo Horie,Yoshiyuki Kakehi,Seiji Naito,Norio Nonomura,Osamu Ogawa,Mototsugu Oya,Kazuhiro Suzuki,Atsushi Saito,Satoshi Uno,Hideyuki Akaza

BJUI compass（2022）

引用 7|浏览6

暂无评分

摘要

First-line AAT with enzalutamide + ADT provided a significant improvement in time to PSA progression versus flutamide + ADT. Enzalutamide + ADT may therefore be the preferred first-line AAT option in Japanese men with metastatic or nonmetastatic CRPC who progress despite CAB with bicalutamide + ADT.

查看译文

关键词

AFTERCAB,Japan,alternative androgen therapy,androgen deprivation therapy,bicalutamide,castration‐resistant prostate cancer,combined androgen blockade,enzalutamide,flutamide,prostate‐specific antigen progression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要